A Phase I Safety Study of Farletuzumab (MORAb-003), Carboplatin and Pegylated Liposomal Doxorubicin (PLD) in Subjects With Platinum-sensitive Ovarian Cancer

Inclusion Criteria:

- Diagnosis of epithelial ovarian cancer

- Must have measurable disease by CT or MRI scan

- Must have relapsed as defined by CA-125 or radiologically within 6 months or more of
completion of first- or second-line platinum chemotherapy

- Must have been treated with surgery and be a candidate for repeat carboplatin therapy

- Must have a normal cardiac ejection fraction at baseline

Exclusion Criteria:

- Subjects who never responded to first- or second-line platinum-based chemotherapy or
whose relapse occurs <6 months from the last platinum therapy

- Subjects who have received other therapy to treat their ovarian cancer since last
relapse

- Known central nervous system tumor involvement

- Evidence of other active invasive malignancy

- Clinically significant heart disease

- Known allergic reaction to a prior monoclonal antibody therapy or have any documented
HAHA

- Previous treatment with MORAb 003 (farletuzumab)

- Previous treatment with anthracyclines

- Clinical contraindications to use PLD